Pitt team redesigns an epilepsy drug

A Pitt team has redesigned the structural components of an existing epilepsy drug--retigabine--in order to make it a more potent, targeted therapy. The older drug activated all 5 types of potassium transport channels in the KCNQ category, but only two were necessary for stabilizing the membranes of brain cells. And the same approach could also work against tinnitus. Release

Suggested Articles

Researchers discovered that inactivating a subtype of the protein beta-arrestin-2 in mice restored the ability of the brain to dispose of toxic tau.

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.